Biohaven Ltd. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Biohaven is a clinical-stage biopharmaceutical company developing treatments in neuroscience, immunology and oncology. It reported no product revenue and continues to fund operations primarily through capital raises and other financing.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $156.0 million | $63.5 million |
| General and administrative expense | $27.3 million | $14.3 million |
| Operating loss | $183.2 million | $77.8 million |
| Net loss / loss per share | $179.5 million / $2.20 | $70.5 million / $1.03 |
| Net cash used in operating activities | $102.6 million | $77.6 million |
- At March 31, cash and cash equivalents were $182.7 million and marketable securities were $100.7 million, totaling $283.4 million in cash and marketable securities. Current assets were $348.7 million; current liabilities were $86.6 million.
- Total liabilities were $117.1 million, including operating lease liabilities; the filing reports no borrowings or other debt balance.
- Cash, cash equivalents and restricted cash decreased $65.2 million during the quarter. Investing activities provided $34.0 million, primarily reflecting maturities of marketable securities.
- Share-based compensation rose to $34.9 million from $3.8 million, contributing to higher R&D and G&A expenses. R&D growth also reflected advancing trials, preclinical work and acquisition-related costs.
Material changes and notable transactions
- Operating expenses increased $105.5 million year over year. R&D increased $92.5 million and G&A increased $12.9 million. Other income declined $3.9 million, primarily because Q1 2023 included transition-services income from the former parent.
- In January, Biohaven acquired Pyramid Biosciences. The acquisition added the TROP-2 antibody-drug conjugate BHV-1510; the upfront share consideration and a developmental milestone were recorded as R&D expense.
- On April 22, 2024, after quarter-end, Biohaven completed a public offering of 6,451,220 shares at $41 per share, raising approximately $247.8 million net for general corporate purposes.
- On May 3, 2024, Biohaven amended its Knopp agreement. The amendment removes commercial sales milestones and reduces potential Kv7 development/regulatory milestones, while replacing tiered royalties with a mid-single-digit royalty. In return, Biohaven agreed to issue shares valued at approximately $75 million within 60 days and approximately $75 million on the first anniversary, and issued a warrant for 294,195 shares at $67.98, subject to conditions. Knopp also received conditional cash true-up rights.
Outlook, risks and contingencies
- Management expects cash, cash equivalents and marketable securities to fund forecast expenses and commitments for more than one year, but says additional capital will be required until the company is profitable. Financing may dilute shareholders or be unavailable on acceptable terms; management says programs or spending could be delayed or reduced if funding is insufficient.
- Management expects significant R&D spending to continue as clinical and preclinical programs advance. No product-sale revenue is expected in the near future; timing and success of development, approval and commercialization remain uncertain.
- Operational milestones cited include expected SMA Phase 3 topline results in the second half of 2024; a planned BHV-2000 Phase 2 obesity study in the second half of 2024; and anticipated second-half 2024 study starts for several other candidates. BHV-7000 epilepsy trials began enrolling in Q1; additional epilepsy and mood-disorder studies were initiated in Q2.
- For troriluzole in OCD, the independent Data Monitoring Committee reviewed the first Phase 3 trial’s interim analysis and recommended that the study continue; the company expects full enrollment in Q1 2025. An interim analysis for the second trial is anticipated in Q4 2024.
- Regulatory risk remains material: the FDA declined to review Biohaven’s SCA3 NDA because the pivotal study missed its primary endpoint. Biohaven reports continued FDA discussions; its European application is under review.
- Potential future payments under license and acquisition agreements are substantial but generally contingent on milestones or sales and were not recorded as liabilities where triggering events were not considered probable. The filing identifies no material pending legal proceedings.
Key investor verification points
- Track quarterly operating cash use against available liquidity, including the impact of the April offering and any subsequent financing or share issuance.
- Review dilution and the full economic impact of the Knopp amendment, including the two share issuances, warrant terms, true-up provisions and revised royalty and milestone obligations.
- Monitor clinical enrollment, interim and topline results, especially the OCD Phase 3 program, SMA Phase 3 trial and BHV-7000 studies.
- Follow FDA and EMA decisions and interactions for troriluzole in SCA3, given the missed primary endpoint and FDA’s prior refusal to review the application.
- Confirm actual development spending, share-based compensation and milestone payments against the company’s plans and funding assumptions.